Comparison of Extra-Virgin and Refined Olive Oil on Some Cardiovascular Risk Factors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2019-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Consumption of extra-virgin olive oil has beneficial effects on cardiovascular risk factors. The purpose of this study is to compare the effects of extra-virgin olive oil and refined olive oil, in adjunct to conventional medical treatment, in improving liver enzymes, plasma lipid profile and inflammatory markers in patients with cardiovascular risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Acute Effect of Novel Olive Oil on Postprandial Oxidative Stress Biomarkers (BioliveCT)

NCT05771571

Cardiometabolic Risk

COMPLETED NA

Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women

NCT03820336

Hypertension Vascular Stiffness

UNKNOWN NA

Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations

NCT01479699

Absorption and Metabolism Effect on Vascular Function Effect on Cytokine Concentrations

COMPLETED NA

Nutritional Intervention With Table Olives in Healthy Volunteers

NCT03886597

Healthy Biological Availability Nutritional Intervention +2 more

COMPLETED PHASE1/PHASE2

The Effect of Olive Leaf Extract on Blood Pressure in Overweight Prehypertensives

NCT01796561

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized placebo controlled clinical trial will be conducted in Rajaie Cardiovascular Center in Tehran, Iran. After review of the inclusion and exclusion criteria and explanation of the design of the study, written consent form will be completed. The participants are 40 eligible patients, aged 20-75 years. Intervention group will be received 25 mL/d extra-virgin olive oil and control group will be received 25 mL/d refined olive oil for 6 weeks. Fasting blood sample will be taken to measure lipid profile, liver enzymes and inflammatory markers (Interleukine-6 \[IL-6\] and Interleukine-10 \[IL-10\] and C-Reactive Protein \[CRP\]).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extra-Virgin Olive Oil

Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks

Group Type ACTIVE_COMPARATOR

Extra-Virgin Olive Oil

Intervention Type DIETARY_SUPPLEMENT

Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks

Refined Olive Oil

Daily consumption of 25 mL Refined Olive Oil for 6 weeks

Group Type PLACEBO_COMPARATOR

Refined Olive Oil

Intervention Type DIETARY_SUPPLEMENT

Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extra-Virgin Olive Oil

Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks

Intervention Type DIETARY_SUPPLEMENT

Refined Olive Oil

Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients with at least one of the cardiovascular risk factors (hypertension, hyperlipidemia, diabetes mellitus) candidate for angiography
2. willing to participation in the study

Exclusion Criteria

1. Continuous consumption of any supplement with anti-inflammatory or antioxidant properties such as Omega-3, vitamin E, vitamin C and Selenium in last month
2. َChronic kidney disease stage 5
3. Any change in disease treatment plan such as change in type and dose of lipid lowering drugs or surgical operation

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No